In vivo gene editing via homology-independent targeted integration for adrenoleukodystrophy treatment

Sung Ah Hong; Jung Hwa Seo; Soohyun Wi; Eul Sik Jung; Jihyeon Yu; Gue Ho Hwang; Ji Hea Yu; Ahreum Baek; Soeon Park; Sangsu Bae; Sung Rae Cho

doi:10.1016/j.ymthe.2021.05.022

In vivo gene editing via homology-independent targeted integration for adrenoleukodystrophy treatment

Sung Ah Hong, Jung Hwa Seo, Soohyun Wi, Eul Sik Jung, Jihyeon Yu, Gue Ho Hwang, Ji Hea Yu, Ahreum Baek, Soeon Park, Sangsu Bae, Sung Rae Cho

Department of Rehabilitation Medicine

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

Adrenoleukodystrophy (ALD) is caused by various pathogenic mutations in the X-linked ABCD1 gene, which lead to metabolically abnormal accumulations of very long-chain fatty acids in many organs. However, curative treatment of ALD has not yet been achieved. To treat ALD, we applied two different gene-editing strategies, base editing and homology-independent targeted integration (HITI), in ALD patient-derived fibroblasts. Next, we performed in vivo HITI-mediated gene editing using AAV9 vectors delivered via intravenous administration in the ALD model mice. We found that the ABCD1 mRNA level was significantly increased in HITI-treated mice, and the plasma levels of C24:0-LysoPC (lysophosphatidylcholine) and C26:0-LysoPC, sensitive diagnostic markers for ALD, were significantly reduced. These results suggest that HITI-mediated mutant gene rescue could be a promising therapeutic strategy for human ALD treatment.

Original language	English
Pages (from-to)	119-129
Number of pages	11
Journal	Molecular Therapy
Volume	30
Issue number	1
DOIs	https://doi.org/10.1016/j.ymthe.2021.05.022
Publication status	Published - 2022 Jan 5

Bibliographical note

Funding Information:
We thank Prof. Hyongbum (Henry) Kim for helpful comments during this study. This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea ( HI16C1012 to S.B. and S.-R.C.) and the Bio & Medical Technology Development Program of the National Research Foundation ( 2020M3A9I4036072 to S.B.).

Publisher Copyright:
© 2021 The American Society of Gene and Cell Therapy

All Science Journal Classification (ASJC) codes

Molecular Medicine
Molecular Biology
Genetics
Pharmacology
Drug Discovery

Access to Document

10.1016/j.ymthe.2021.05.022

Cite this

@article{778195a795504a4a95370574cf676320,

title = "In vivo gene editing via homology-independent targeted integration for adrenoleukodystrophy treatment",

abstract = "Adrenoleukodystrophy (ALD) is caused by various pathogenic mutations in the X-linked ABCD1 gene, which lead to metabolically abnormal accumulations of very long-chain fatty acids in many organs. However, curative treatment of ALD has not yet been achieved. To treat ALD, we applied two different gene-editing strategies, base editing and homology-independent targeted integration (HITI), in ALD patient-derived fibroblasts. Next, we performed in vivo HITI-mediated gene editing using AAV9 vectors delivered via intravenous administration in the ALD model mice. We found that the ABCD1 mRNA level was significantly increased in HITI-treated mice, and the plasma levels of C24:0-LysoPC (lysophosphatidylcholine) and C26:0-LysoPC, sensitive diagnostic markers for ALD, were significantly reduced. These results suggest that HITI-mediated mutant gene rescue could be a promising therapeutic strategy for human ALD treatment.",

author = "Hong, {Sung Ah} and Seo, {Jung Hwa} and Soohyun Wi and Jung, {Eul Sik} and Jihyeon Yu and Hwang, {Gue Ho} and Yu, {Ji Hea} and Ahreum Baek and Soeon Park and Sangsu Bae and Cho, {Sung Rae}",

note = "Funding Information: We thank Prof. Hyongbum (Henry) Kim for helpful comments during this study. This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea ( HI16C1012 to S.B. and S.-R.C.) and the Bio & Medical Technology Development Program of the National Research Foundation ( 2020M3A9I4036072 to S.B.). Publisher Copyright: {\textcopyright} 2021 The American Society of Gene and Cell Therapy",

year = "2022",

month = jan,

day = "5",

doi = "10.1016/j.ymthe.2021.05.022",

language = "English",

volume = "30",

pages = "119--129",

journal = "Molecular Therapy",

issn = "1525-0016",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - In vivo gene editing via homology-independent targeted integration for adrenoleukodystrophy treatment

AU - Hong, Sung Ah

AU - Seo, Jung Hwa

AU - Wi, Soohyun

AU - Jung, Eul Sik

AU - Yu, Jihyeon

AU - Hwang, Gue Ho

AU - Yu, Ji Hea

AU - Baek, Ahreum

AU - Park, Soeon

AU - Bae, Sangsu

AU - Cho, Sung Rae

N1 - Funding Information: We thank Prof. Hyongbum (Henry) Kim for helpful comments during this study. This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea ( HI16C1012 to S.B. and S.-R.C.) and the Bio & Medical Technology Development Program of the National Research Foundation ( 2020M3A9I4036072 to S.B.). Publisher Copyright: © 2021 The American Society of Gene and Cell Therapy

PY - 2022/1/5

Y1 - 2022/1/5

N2 - Adrenoleukodystrophy (ALD) is caused by various pathogenic mutations in the X-linked ABCD1 gene, which lead to metabolically abnormal accumulations of very long-chain fatty acids in many organs. However, curative treatment of ALD has not yet been achieved. To treat ALD, we applied two different gene-editing strategies, base editing and homology-independent targeted integration (HITI), in ALD patient-derived fibroblasts. Next, we performed in vivo HITI-mediated gene editing using AAV9 vectors delivered via intravenous administration in the ALD model mice. We found that the ABCD1 mRNA level was significantly increased in HITI-treated mice, and the plasma levels of C24:0-LysoPC (lysophosphatidylcholine) and C26:0-LysoPC, sensitive diagnostic markers for ALD, were significantly reduced. These results suggest that HITI-mediated mutant gene rescue could be a promising therapeutic strategy for human ALD treatment.

AB - Adrenoleukodystrophy (ALD) is caused by various pathogenic mutations in the X-linked ABCD1 gene, which lead to metabolically abnormal accumulations of very long-chain fatty acids in many organs. However, curative treatment of ALD has not yet been achieved. To treat ALD, we applied two different gene-editing strategies, base editing and homology-independent targeted integration (HITI), in ALD patient-derived fibroblasts. Next, we performed in vivo HITI-mediated gene editing using AAV9 vectors delivered via intravenous administration in the ALD model mice. We found that the ABCD1 mRNA level was significantly increased in HITI-treated mice, and the plasma levels of C24:0-LysoPC (lysophosphatidylcholine) and C26:0-LysoPC, sensitive diagnostic markers for ALD, were significantly reduced. These results suggest that HITI-mediated mutant gene rescue could be a promising therapeutic strategy for human ALD treatment.

UR - http://www.scopus.com/inward/record.url?scp=85113975275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85113975275&partnerID=8YFLogxK

U2 - 10.1016/j.ymthe.2021.05.022

DO - 10.1016/j.ymthe.2021.05.022

M3 - Article

C2 - 34058389

AN - SCOPUS:85113975275

SN - 1525-0016

VL - 30

SP - 119

EP - 129

JO - Molecular Therapy

JF - Molecular Therapy

IS - 1

ER -

In vivo gene editing via homology-independent targeted integration for adrenoleukodystrophy treatment

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this